Skip to content
10-Q

Quarterly Report

APELLIS PHARMACEUTICALS, INC.

0001492422-26-000108

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 128.02M sh
Shares Diluted Q1 2026 · Mar 31, 2026 131.42M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 125.45M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$60.97M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$53.41M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $405.21M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $466.23M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $358.39M
Stockholders Equity Q1 2026 · Mar 31, 2026 $414.92M
Stockholders Equity Q1 2026 · Dec 31, 2025 $370.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 $164.22M
Stockholders Equity Q1 2026 · Dec 31, 2024 $228.54M
Current Liabilities Q1 2026 · Mar 31, 2026 $283.45M
Current Liabilities Q1 2026 · Dec 31, 2025 $323.6M
Total Liabilities Q1 2026 · Mar 31, 2026 $667.61M
Total Liabilities Q1 2026 · Dec 31, 2025 $705.11M
Current Assets Q1 2026 · Mar 31, 2026 $1.03B
Current Assets Q1 2026 · Dec 31, 2025 $1.01B
Total Assets Q1 2026 · Mar 31, 2026 $1.08B
Total Assets Q1 2026 · Dec 31, 2025 $1.08B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.15
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.74
Eps Basic Q1 2026 · Mar 31, 2026 $0.15
Eps Basic Q1 2026 · Mar 31, 2025 −$0.74
Sga Expense Q1 2026 · Mar 31, 2026 $124.32M
Sga Expense Q1 2026 · Mar 31, 2025 $129.35M
Rd Expense Q1 2026 · Mar 31, 2026 $76.96M
Rd Expense Q1 2026 · Mar 31, 2025 $86.42M
Net Income Q1 2026 · Mar 31, 2026 $18.66M
Net Income Q1 2026 · Mar 31, 2025 −$92.23M
Operating Income Q1 2026 · Mar 31, 2026 $26.47M
Operating Income Q1 2026 · Mar 31, 2025 −$83.33M
Revenue Q1 2026 · Mar 31, 2026 $268.3M
Revenue Q1 2026 · Mar 31, 2025 $166.8M
Capex Q1 2026 · Mar 31, 2025 $8K